[{"address1": "4300 El Camino Real", "address2": "Suite 210", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 351 4495", "website": "https://unicycive.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.", "fullTimeEmployees": 14, "companyOfficers": [{"maxAge": 1, "name": "Dr. Shalabh K. Gupta M.D., MPA", "age": 50, "title": "Founder, Chairman, CEO & President", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1100000, "exercisedValue": 0, "unexercisedValue": 141224}, {"maxAge": 1, "name": "Dr. Pramod  Gupta Ph.D.", "age": 63, "title": "Executive Vice President of Pharmaceutical & Business Operations", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 675000, "exercisedValue": 0, "unexercisedValue": 40969}, {"maxAge": 1, "name": "Mr. Douglas  Jermasek M.B.A.", "age": 61, "title": "Executive Vice President of Corporate Strategy", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 412500, "exercisedValue": 0, "unexercisedValue": 42029}, {"maxAge": 1, "name": "Mr. John W. Townsend CPA", "age": 61, "title": "Chief Financial Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 197864, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.431, "open": 0.4275, "dayLow": 0.3932, "dayHigh": 0.43, "regularMarketPreviousClose": 0.431, "regularMarketOpen": 0.4275, "regularMarketDayLow": 0.3932, "regularMarketDayHigh": 0.43, "beta": 2.348, "forwardPE": -2.031, "volume": 1213853, "regularMarketVolume": 1213853, "averageVolume": 2271126, "averageVolume10days": 1263030, "averageDailyVolume10Day": 1263030, "marketCap": 38327488, "fiftyTwoWeekLow": 0.202, "fiftyTwoWeekHigh": 1.818, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 0.3819, "twoHundredDayAverage": 0.819555, "currency": "USD", "enterpriseValue": 43368492, "floatShares": 61454201, "sharesOutstanding": 94356200, "sharesShort": 993824, "sharesShortPriorMonth": 746813, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0105, "heldPercentInsiders": 0.06734, "heldPercentInstitutions": 0.39925, "shortRatio": 0.6, "shortPercentOfFloat": 0.0114, "bookValue": -0.341, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -24406000, "trailingEps": -0.36, "forwardEps": -0.2, "enterpriseToEbitda": -1.504, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "UNCY", "underlyingSymbol": "UNCY", "shortName": "Unicycive Therapeutics, Inc.", "longName": "Unicycive Therapeutics, Inc.", "firstTradeDateEpochUtc": 1626096600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8b289956-33cd-3aa2-beed-9487631afaeb", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.4062, "targetHighPrice": 9.0, "targetLowPrice": 2.0, "targetMeanPrice": 5.25, "targetMedianPrice": 5.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 41780000, "totalCashPerShare": 0.443, "ebitda": -28842000, "totalDebt": 634000, "quickRatio": 3.193, "currentRatio": 3.366, "debtToEquity": 2.023, "returnOnAssets": -0.53371, "returnOnEquity": -1.21763, "freeCashflow": -16685250, "operatingCashflow": -21636000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]